Irm LLC

Novartis Ag

The Scripps Research Institute

Novartis Pharma Gmbh

Shifeng Pan

Wenqi Gao

Yongqin Wan

Nathanael Schiander Gray

Dai Cheng

Yuan Mi

Dong Han

Guobao Zhang

Xing Wang

Yi Liu

Donald Karanewsky

Yi Fan

Jiqing Jiang

Pascal Furet

Xiaolin Li

Valentina Molteni

Vito Guagnano

Jon Christopher Loren

Juliet Nabakka

Donatella Chianelli

Shuli You

Tao Jiang

Yongping Xie

Xiaodong Liu

John Tellew

Xia Wang

Yun Feng Xie

Peter G Schultz

Qiong Zhang

Shenlin Huang

Tetsuo Uno

Bernhard Hubert Geierstanger

Zuosheng Liu

Michael P Cooke

Weijia Ou

Wenshuo Lu

Jan Grunewald

Anthony E Boitano

Sophie Lefebvre

Yang Yang

Pingda Ren

Pamela Ann Albaugh

Paul A Renhowe

Chengzhi Zhang

Yun He

Daniel J Poon

Martin Sendzik

Qiang Ding

Lawrence Blas Perez

Badry Bursulaya

John E Monahan

Nathanael S Gray

Thomas H Marsilje, Iii

Peter Ettmayer

Junbiao Chang

Klaus Hinterding

Gregory B Chopiuk

Peter Nussbaumer

Xu Wu

Yahua Liu

Qihui Jin

Wei Wang

John E Tellew

Thomas Marsilje

Rajender Reddy Leleti

Wenqui Gao

Federic Zecri

Fan Yi

Kenneth Richad La Montagne

Lichun Shen

Marion Dorsch

Michael Patrick Morrissey

Juliet Williams

Xiadong Liu

Kenneth Richard La Montagne

Donald S Karanewsky

Ying Fan

Frédéric Zecri

Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

Cytotoxic peptides and conjugates thereof

The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), 

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators

Auristatin derivatives and conjugates thereof

The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.

Compounds that expand hematopoietic stem cells

The present invention relates to compositions and methods for modulating the Wnt signaling pathway.

N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as WNT signaling modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I).

Hedgehog pathway modulators

The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R, R, Rand Rare defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. 

N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors

The present invention relates to compositions and methods for modulating the Wnt signaling pathway, using compounds having Formula (1) and (3): wherein A, B, Y and Z all represent rings, and R, R, Rare as defined herein. 

Substituted pyridines for modulating the WNT signaling pathway

Method for expanding hematopoietic stem cells

The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

Smoothened antagonism for the treatment of hedgehog pathway-related disorders

The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A, A, B, Y and Z all represent rings. 

N-(hetero)aryl, 2-(hetero)aryl&#x2014;substituted acetamides for use as Wnt signaling modulators

The invention provides a method, compounds and compositions for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or GIi gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula (I). 

Compounds and compositions as hedgehog pathway inhibitors

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

Compounds and compositions as protein kinase inhibitors

The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb). 

Compounds and compositions as ITPKb inhibitors

The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

Compounds and compositions as hedgehog pathway modulators

Growing community of inventors

San Diego, CA, United States of America

Shifeng Pan